1. Home
  2. INBK vs HELP Comparison

INBK vs HELP Comparison

Compare INBK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Internet Bancorp

INBK

First Internet Bancorp

HOLD

Current Price

$25.64

Market Cap

179.3M

Sector

Finance

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$4.25

Market Cap

214.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBK
HELP
Founded
1999
N/A
Country
United States
Canada
Employees
355
50
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.3M
214.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
INBK
HELP
Price
$25.64
$4.25
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$23.25
$51.50
AVG Volume (30 Days)
33.3K
602.3K
Earning Date
04-30-2026
07-01-2026
Dividend Yield
1.06%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$279.34
N/A
Revenue Next Year
$12.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.05
$3.76
52 Week High
$28.51
$8.55

Technical Indicators

Market Signals
Indicator
INBK
HELP
Relative Strength Index (RSI) 59.63 44.48
Support Level $23.14 $4.22
Resistance Level N/A $4.75
Average True Range (ATR) 0.94 0.27
MACD 0.12 0.02
Stochastic Oscillator 74.44 50.51

Price Performance

Historical Comparison
INBK
HELP

About INBK First Internet Bancorp

First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: